Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 5/20 | 0.45 |
| ▸ | GSK3A | P49840 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | PTK2 | Q05397 | 11/20 | 0.44 |
| ▸ | LCK | P06239 | 2/20 | 0.41 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.41 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.41 |
| ▸ | KIT | P10721 | 1/20 | 0.41 |
| ▸ | FLT3 | P36888 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15524522 | 0.91 | CCNA2 (0.51) | JAK3GSK3AGSK3BPTK2 | |
| SCHEMBL15524018 | 0.91 | PTK2 (0.44) | JAK3GSK3AGSK3BPTK2NTRK1 | |
| SCHEMBL12478740 | 0.90 | PTK2 (0.53) | PTK2 | |
| SCHEMBL12478690 | 0.90 | PTK2 (0.53) | JAK3GSK3AGSK3BPTK2 | |
| SCHEMBL12478260 | 0.87 | PTK2 (0.54) | PTK2 | |
| SCHEMBL15524830 | 0.86 | PTK2 (0.49) | PTK2 | |
| SCHEMBL12479026 | 0.84 | PTK2 (0.51) | PTK2 | |
| SCHEMBL15524349 | 0.84 | FLT4 (0.52) | PTK2KITFLT3 | |
| SCHEMBL12478056 | 0.84 | PTK2 (0.53) | PTK2 | |
| SCHEMBL15524715 | 0.83 | CCNA2 (0.51) | GSK3AGSK3BPTK2NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9266864-B2 | VEGFR3 inhibitors | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2016-02-23 | — | — | US | disclosed |
| US-20150225377-A1 | VEGFR3 INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2015-08-13 | — | — | US | disclosed |
| US-20140080798-A1 | VEGFR3 INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2014-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225377-A1 | VEGFR3 INHIBITORS | FLT4, FLT1, KDR | JAK3 26/4885GSK3A 446/4885GSK3B 283/4885 |
| US-20140080798-A1 | VEGFR3 INHIBITORS | FLT4, FLT1, KDR | JAK3 26/4885GSK3A 419/4885GSK3B 294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.